Cosentyx Europska Unija - hrvatski - EMA (European Medicines Agency)

cosentyx

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Dupixent Europska Unija - hrvatski - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

COSENTYX (▼) 150 mg/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cosentyx (▼) 150 mg/1 ml rastvor za injekciju u napunjenom penu

novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba

COSENTYX (▼) 150 mg/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cosentyx (▼) 150 mg/1 ml rastvor za injekciju u napunjenom penu

novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba

Adtralza Europska Unija - hrvatski - EMA (European Medicines Agency)

adtralza

leo pharma a/s - tralokinumab - dermatitis, atopic - ostali dermatološki pripravci - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

COSENTYX 150 mg/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cosentyx 150 mg/1 ml rastvor za injekciju u napunjenom penu

novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba

COSENTYX 150 mg/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cosentyx 150 mg/1 ml rastvor za injekciju u napunjenom penu

novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba

INFANRIX Hexa ≥ 30 i.j./0.5 mL+ ≥ 40 i.j./0.5 mL+ 25 µg/0.5 mL+ 25 µg/0.5 mL+ 8 µg/0.5 mL+ 10 µg/0.5 mL+ 40 AgU/0.5 mL+ 8 AgU/0. Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

infanrix hexa ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.

evropa lijek pharma d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa, hepatitisa b - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32 agu/0 - 0,5 ml suspenzije za injekciju (1 doza) sadrži: ne manje od 30 i.j. toksoid difterije, adsorbovani ne manje od 40 i.j. toksoid tetanusa, adsorbovani 25 mcg pertusis toksoid, adsorbovani 25 mcg filamentozni hemaglutinin, adsorbovani 8 mcg pertaktin, adsorbovani 10 mcg površinski antigen hepatitis b virusa 40 dantigen jedinica polio virus, inaktivirani, tip 1 8 dantigen jedinica polio virus, inaktivirani, tip 2 32 dantigen jedinica polio virus, in aktivirani, tip 3 10 mcg polisaharid hemofilusa tip b (konjugovan na toksoid tetanusa), adsorbovani

COSENTYX 75 mg/0.5 mL rastvor za injekciju u napunjenoj šprici Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cosentyx 75 mg/0.5 ml rastvor za injekciju u napunjenoj šprici

novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenoj šprici - 75 mg/0.5 ml - 1 napunjena šprica od 0,5 ml rastvora za injekcije sadrži : 75 mg sekukinumaba

INFANRIX Hexa ≥ 30 i.j./0.5 mL+ ≥ 40 i.j./0.5 mL+ 25 µg/0.5 mL+ 25 µg/0.5 mL+ 8 µg/0.5 mL+ 10 µg/0.5 mL+ 40 AgU/0.5 mL+ 8 AgU/0. Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

infanrix hexa ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.

glaxosmithkline d.o.o.sarajevo - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa, hepatitisa b - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 10 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32 agu/0 - 0,5 ml suspenzije za injekciju (1 doza) sadrži: ne manje od 30 i.j. toksoid difterije, adsorbovani ne manje od 40 i.j. toksoid tetanusa, adsorbovani 25 mcg pertusis toksoid, adsorbovani 25 mcg filamentozni hemaglutinin, adsorbovani 8 mcg pertaktin, adsorbovani 10 mcg površinski antigen hepatitis b virusa 40 dantigen jedinica polio virus, inaktivirani, tip 1 8 dantigen jedinica polio virus, inaktivirani, tip 2 32 dantigen jedinica polio virus, in aktivirani, tip 3 10 mcg polisaharid hemofilusa tip b (konjugovan na toksoid tetanusa), adsorbovani